Artesunate-Clindamycin versus Quinine-Clindamycin in the Treatment ofPlasmodium falciparum Malaria: A Randomized Controlled Trial | Zendy

P. G. Kremsner | Zendy; Michael Ramharter | Zendy; Sunny Oyakhirome | Zendy; P. K. Klouwenberg | Zendy; Ayôla Akim Adégnika | Zendy; S. T. Agnandji | Zendy; Michel A. Missinou | Zendy; P.-B. Matsiegui | Zendy; Benjamin Mordmüller | Zendy; Steffen Borrmann | Zendy; J. F. Kun | Zendy; B. Lell | Zendy; Sanjeev Krishna | Zendy; W. Graninger | Zendy; S. Issifou | Zendy

Open Access

Artesunate-Clindamycin versus Quinine-Clindamycin in the Treatment ofPlasmodium falciparum Malaria: A Randomized Controlled Trial

Author(s) -

P. G. Kremsner,

Michael Ramharter,

Sunny Oyakhirome,

P. K. Klouwenberg,

Ayôla Akim Adégnika,

S. T. Agnandji,

Michel A. Missinou,

P.-B. Matsiegui,

Benjamin Mordmüller,

Steffen Borrmann,

J. F. Kun,

B. Lell,

Sanjeev Krishna,

W. Graninger,

S. Issifou

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/430309

Subject(s) - artesunate , medicine , clindamycin , tolerability , artemisinin , quinine , malaria , plasmodium falciparum , population , regimen , adverse effect , pharmacology , antibiotics , immunology , biology , microbiology and biotechnology , environmental health

Artemisinin-based drug combinations are the mainstay in the fight against drug-resistant malaria in Africa. Currently available antimalarial drug combinations that include artemisinins are pharmacokinetically unmatched and are therefore potentially increasing the risk of selection of resistant mutants in areas in which the rate of transmission of malaria is high. We tested the potential value of artemisinin-based combination therapy with a short elimination half-life for the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research